Group 1 - WuXi AppTec reported a 20.96% year-on-year increase in revenue for Q1 2025, reaching 9.655 billion yuan, and a net profit of 3.672 billion yuan, reflecting an 89.06% growth [1] - The strong growth momentum highlights WuXi AppTec's competitive strength and leading position in the pharmaceutical research and development service sector [1] Group 2 - Paig Bio has passed the hearing for its upcoming IPO on the Hong Kong Stock Exchange, with a valuation of 4 billion yuan after 8 rounds of financing [2] - The company focuses on innovative therapies for chronic diseases, and despite a net loss of 283 million yuan in 2024, it has significant potential for its core products [2] Group 3 - Merck KGaA announced its acquisition of SpringWorks for approximately 3.9 billion USD, which is a strategic move to enhance its oncology portfolio [3] - SpringWorks specializes in developing drugs for cancer and rare tumors, with products like Ogsiveo and Gomekli, which will strengthen Merck's position in cancer treatment [3] Group 4 - The European Union has approved a Phase III clinical trial for HLX22, a novel anti-HER2 monoclonal antibody, in combination with trastuzumab and chemotherapy for HER2-positive gastric cancer [4] - This approval offers new hope for patients with HER2-positive gastric cancer, as there are currently no similar dual-target therapies approved globally [4] Group 5 - Likang Life Sciences has successfully administered the first dose of its AI-driven personalized mRNA tumor vaccine, marking a significant breakthrough in China's tumor immunotherapy field [5] - This development is expected to usher in a new era of personalized cancer treatment, providing new hope for patients with advanced solid tumors [5]